Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia

被引：5

作者：

Cafforio, Luciana ^{[1
]}

Raponi, Sara ^{[1
]}

Cappelli, Luca Vincenzo ^{[1
]}

Ilari, Caterina ^{[1
]}

Soscia, Roberta ^{[1
]}

De Propris, Maria Stefania ^{[1
]}

Mariglia, Paola ^{[1
]}

Rigolin, Gian Matteo ^{[2
]}

Bardi, Antonella ^{[2
]}

Peragine, Nadia

Piciocchi, Alfonso ^{[3
]}

Arena, Valentina ^{[3
]}

Mauro, Francesca Romana ^{[1
]}

Cuneo, Antonio

Guarini, Anna ^{[4
]}

Foa, Robin ^{[1
]}

Del Giudice, Ilaria ^{[1
]}

机构：

[1] Sapienza Univ, Hematol Sect, Dept Translat & Precis Med, Rome, Italy

[2] Univ Ferrara, Azienda Osped Univ Arcispedale S Anna, Dept Med Sci, Hematol Sect, Ferrara, Italy

[3] GIMEMA Fdn, GIMEMA Data Ctr, Rome, Italy

[4] Sapienza Univ, Dept Mol Med, Rome, Italy

来源：

HAEMATOLOGICA | 2022年 / 107卷 / 01期

关键词：

CLINICAL IMPACT; RESISTANCE; MUTATIONS;

D O I：

10.3324/haematol.2020.263715

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：334 / 337

页数：4

共 50 条

[31] ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
S Pospisilova
D Gonzalez
J Malcikova
M Trbusek
D Rossi
A P Kater
F Cymbalista
B Eichhorst
M Hallek
H Döhner
P Hillmen
M van Oers
J Gribben
P Ghia
E Montserrat
S Stilgenbauer
T Zenz
Leukemia, 2012, 26 : 1458 - 1461
[32] ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
Pospisilova, S.
Gonzalez, D.
Malcikova, J.
Trbusek, M.
Rossi, D.
Kater, A. P.
Cymbalista, F.
Eichhorst, B.
Hallek, M.
Doehner, H.
Hillmen, P.
van Oers, M.
Gribben, J.
Ghia, P.
Montserrat, E.
Stilgenbauer, S.
Zenz, T.
LEUKEMIA, 2012, 26 (07) : 1458 - 1461
[33] TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia
Zainuddin, Norafiza
Murray, Fiona
Kanduri, Meena
Gunnarsson, Rebeqa
Smedby, Karin E.
Enblad, Gunilla
Jurlander, Jesper
Juliusson, Gunnar
Rosenquist, Richard
LEUKEMIA RESEARCH, 2011, 35 (02) : 272 - 274
[34] Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study
Visentin, Andrea
Mauro, Francesca Romana
Scarfo, Lydia
Gentile, Massimo
Farina, Lucia
Reda, Gianluigi
Ferrarini, Isacco
Proietti, Giulia
Derenzini, Enrico
Cibien, Francesca
Vitale, Candida
Sanna, Alessandro
Pietrasanta, Daniela
Marchetti, Monia
Murru, Roberta
Rigolin, Gian Matteo
Sportoletti, Paolo
Trimarco, Valentina
Cavarretta, Chiara Adele
Angotzi, Francesco
Cellini, Alessandro
Ruocco, Valeria
Zatta, Ivan
Laurenti, Luca
Molica, Stefano
Coscia, Marta
Ghia, Paolo
Foa, Robin
Cuneo, Antonio
Trentin, Livio
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (09) : E237 - E240
[35] Clinical Impact of Clonal and Subclonal TP53 Mutations and Deletions in Chronic Lymphocytic Leukemia: An Italian Multicenter Experience
Bomben, Riccardo
Rossi, Francesca Maria
D'Agaro, Tiziana
Bittolo, Tamara
Vit, Filippo
Zucchetto, Antonella
Tissino, Erika
Pozzo, Federico
Ballerini, Mario
Bulian, Pietro
Degan, Massimo
Polesel, Jerry
Zaina, Eva
Cattarossi, Ilaria
Nanni, Paola
Chivilo, Hillarj
D'Arena, Giovanni Francesco
Santinelli, Enrico
Biagi, Annalisa
Chiarenza, Annalisa
Zaja, Francesco
Pozzato, Gabriele
Di Raimondo, Francesco
Rossi, Davide
Del Poeta, Giovanni
Gattei, Valter
BLOOD, 2019, 134
[36] Clinical impact of clonal and subclonal TP53 mutations and deletions in chronic lymphocytic leukemia: an Italian multicenter experience
Bomben, Riccardo
Rossi, Francesca Maria
D'Agaro, Tiziana
Bittolo, Tamara
Vit, Filippo
Zucchetto, Antonella
Tissino, Erika
Pozzo, Federico
Bulian, Pietro
Degan, Massimo
Polesel, Jerry
D'Arena, Giovanni
Santinelli, Enrico
Biagi, Annalisa
Chiarenza, Annalisa
Zaja, Francesco
Pozzato, Gabriele
Di Raimondo, Francesco
Rossi, Davide
Del Poeta, Giovanni
Gattei, Valter
LEUKEMIA & LYMPHOMA, 2020, 61 : 215 - 217
[37] Development of chronic myelogenous leukemia in a case of chronic lymphocytic leukemia with Tp53 gene deletion
Gupta, A.
Parihar, M.
Yadav, A. K.
Chakrapani, A.
JOURNAL OF POSTGRADUATE MEDICINE, 2015, 61 (02) : 137 - +
[38] Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study
Visentin, Andrea
Mauro, Francesca Romana
Cibien, Francesca
Vitale, Candida
Reda, Gianluigi
Fresa, Alberto
Ciolli, Stefania
Pietrasanta, Daniela
Marchetti, Monia
Murru, Roberta
Gentile, Massimo
Rigolin, Gian Matteo
Quaglia, Francesca Maria
Scarfo, Lydia
Sportoletti, Paolo
Pravato, Stefano
Piazza, Francesco
Coscia, Marta
Laurenti, Luca
Molica, Stefano
Foa, Robin
Cuneo, Antonio
Trentin, Livio
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (03) : E95 - E99
[39] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
Jain, Nitin
Thompson, Philip
Burger, Jan
Ferrajoli, Alessandra
Takahashi, Koichi
Estrov, Zeev
Borthakur, Gautam
Bose, Prithviraj
Kadia, Tapan
Pemmaraju, Naveen
Sasaki, Koji
Konopleva, Marina
Jabbour, Elias
Garg, Naveen
Wang, Xuemei
Kanagal-Shamanna, Rashmi
Patel, Keyur
Wang, Wei
Jorgensen, Jeffrey
Wang, Sa
Lopez, Wanda
Ayala, Ana
Plunkett, William
Gandhi, Varsha
Kantarjian, Hagop
O'Brien, Susan
Keating, Michael
Wierda, William G.
LEUKEMIA, 2021, 35 (12) : 3421 - 3429
[40] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
Nitin Jain
Philip Thompson
Jan Burger
Alessandra Ferrajoli
Koichi Takahashi
Zeev Estrov
Gautam Borthakur
Prithviraj Bose
Tapan Kadia
Naveen Pemmaraju
Koji Sasaki
Marina Konopleva
Elias Jabbour
Naveen Garg
Xuemei Wang
Rashmi Kanagal-Shamanna
Keyur Patel
Wei Wang
Jeffrey Jorgensen
Sa Wang
Wanda Lopez
Ana Ayala
William Plunkett
Varsha Gandhi
Hagop Kantarjian
Susan O’Brien
Michael Keating
William G. Wierda
Leukemia, 2021, 35 : 3421 - 3429

← 1 2 3 4 5 →